Scandion Oncology has identified four clinical sites to take part in the planned Phase II clinical trial
Scandion Oncology A/S (“Scandion Oncology” or the “Company”) today announces that the Company has identified the four clinical sites where the lead candidate drug SCO–101 will be tested in combination with chemotherapy in patients with metastatic and drug resistant colorectal cancer. The first patients to enter the trial are expected to be included in December 2019. The four sites are located in Denmark in the Capital Region, Region South, Region North and Region Zealand.CEO Nils Brünner comments: “This is a very important stepping-stone in the quest to prove that SCO–101 can revert